Peter Lio, MD, a dermatologist and clinical assistant professor at Northwestern Feinberg School of Medicine, discusses strategies for managing pediatric atopic dermatitis and how proper management can impact the disease course.
In an interview, Peter Lio, MD, a dermatologist and clinical assistant professor at Northwestern Feinberg School of Medicine, chronicled a number of factors that can impact the disease course of atopic dermatitis in children, including lifestyle and environmental factors.
Lio presented on the topic at the Society for Pediatric Dermatology 2024 annual conference, which was held from July 11 to July 14 in Toronto, Canada.
This transcript has been lightly edited for clarity.
Transcript
How effective are current treatment options in modifying the long-term course of pediatric atopic dermatitis?
This is such a critical question at this time because I think we're seeing a few different competing ideas play out. And the short answer is we don't know. The longer answer is, we think there might be something to this, though.
And the 2 signals are first, that there really is the potential for disease modification, as a concept. And I believe strongly in this because I talk about atopic dermatitis as being a disease of vicious cycles, that the barrier starts to fall apart, the microbiome follows, the immune system responds, then there's a behavioral piece where people are scratching. If you disrupt that it really does seem to follow that you can then go from that vicious cycle downward to a virtuous cycle where everything's getting more back in harmony in a better state that can actually, I think, be resilient. So there's that piece, can we change the course? And I think the answer is probably yes.
The second piece is, can we also change some of the allergic comorbidities that come along with it? And I think, again, tentative maybe. And the reason is, is because we think a lot of allergies happen through this process called epicutaneous, or transcutaneous sensitization. The broken skin barrier allows allergens and irritants to get into the skin.
So if we could heal the skin and protect it from an early point, is it not possible that we could then prevent the progression and development of other diseases? And the answer is maybe. Some of the early studies suggest that there's a signal. There was a neat study showing that aggressive care of atopic dermatitis early on did seem to decrease the development of food allergy in a cohort, but it was kind of a contrived study, so we need to see it play out.
What evidence supports the use of systemic therapies, such as biologics, in changing atopic dermatitis disease progression in children?
I think we understand that undertreated atopic dermatitis is way too common, and we hear it over and over and over. We see patients who are just not where they need to be.
Topicals are amazing for a lot of patients, and I would argue they're also important for everybody, no matter how severe you are. If there's going to be some role for topicals, you're going to be using topicals. But I think a lot of patients really do need to be on a systemic agent, because we know, for example, that even skin that looks normal, is often not really normal. It's sort of normal-ish, but it's not quite baseline. And so we really think there's a role for more systemic therapy. And that really brings up that point of if we treat people appropriately, and I would argue whether or not you need systemic therapy, but if we treat appropriately and many patients, I think do need systemics, I think we potentially can modify the disease or at the very least, enter into a state of relative remission.
This is something I see played out every single day in clinic, where we have people who are out of control, we get them better again—plus or minus systemics. I don't think you always need a systemic. For milder or more limited disease, you might be able to do the same thing with topicals. But for many patients, probably more than we think systemics are helpful. What we find is that we can then decrease their medication, we can increase the interval between it, or sometimes even stop it completely. And that's kind of mind boggling, to see a patient who is totally out of control now saying, "I'm pretty good. I don't really need a whole lot."
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More